Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   282.02 (-0.24%)
AAPL   143.27 (-0.66%)
MSFT   240.77 (-0.41%)
META   109.55 (+0.71%)
GOOGL   95.25 (-0.83%)
AMZN   93.16 (-0.84%)
TSLA   182.71 (-0.11%)
NVDA   158.02 (-0.16%)
NIO   10.75 (+6.23%)
BABA   80.14 (+5.61%)
AMD   73.69 (+0.68%)
T   18.85 (+0.16%)
MU   56.11 (+0.65%)
CGC   3.45 (+1.47%)
F   13.77 (+0.29%)
GE   85.27 (-0.23%)
DIS   96.01 (+0.33%)
AMC   7.21 (-1.64%)
PYPL   80.04 (+0.14%)
PFE   49.50 (-0.14%)
NFLX   279.95 (-0.43%)
QQQ   282.02 (-0.24%)
AAPL   143.27 (-0.66%)
MSFT   240.77 (-0.41%)
META   109.55 (+0.71%)
GOOGL   95.25 (-0.83%)
AMZN   93.16 (-0.84%)
TSLA   182.71 (-0.11%)
NVDA   158.02 (-0.16%)
NIO   10.75 (+6.23%)
BABA   80.14 (+5.61%)
AMD   73.69 (+0.68%)
T   18.85 (+0.16%)
MU   56.11 (+0.65%)
CGC   3.45 (+1.47%)
F   13.77 (+0.29%)
GE   85.27 (-0.23%)
DIS   96.01 (+0.33%)
AMC   7.21 (-1.64%)
PYPL   80.04 (+0.14%)
PFE   49.50 (-0.14%)
NFLX   279.95 (-0.43%)
QQQ   282.02 (-0.24%)
AAPL   143.27 (-0.66%)
MSFT   240.77 (-0.41%)
META   109.55 (+0.71%)
GOOGL   95.25 (-0.83%)
AMZN   93.16 (-0.84%)
TSLA   182.71 (-0.11%)
NVDA   158.02 (-0.16%)
NIO   10.75 (+6.23%)
BABA   80.14 (+5.61%)
AMD   73.69 (+0.68%)
T   18.85 (+0.16%)
MU   56.11 (+0.65%)
CGC   3.45 (+1.47%)
F   13.77 (+0.29%)
GE   85.27 (-0.23%)
DIS   96.01 (+0.33%)
AMC   7.21 (-1.64%)
PYPL   80.04 (+0.14%)
PFE   49.50 (-0.14%)
NFLX   279.95 (-0.43%)
QQQ   282.02 (-0.24%)
AAPL   143.27 (-0.66%)
MSFT   240.77 (-0.41%)
META   109.55 (+0.71%)
GOOGL   95.25 (-0.83%)
AMZN   93.16 (-0.84%)
TSLA   182.71 (-0.11%)
NVDA   158.02 (-0.16%)
NIO   10.75 (+6.23%)
BABA   80.14 (+5.61%)
AMD   73.69 (+0.68%)
T   18.85 (+0.16%)
MU   56.11 (+0.65%)
CGC   3.45 (+1.47%)
F   13.77 (+0.29%)
GE   85.27 (-0.23%)
DIS   96.01 (+0.33%)
AMC   7.21 (-1.64%)
PYPL   80.04 (+0.14%)
PFE   49.50 (-0.14%)
NFLX   279.95 (-0.43%)
NASDAQ:DFFN

Diffusion Pharmaceuticals - DFFN Stock Forecast, Price & News

$5.78
-0.39 (-6.32%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.72
$6.12
50-Day Range
$4.64
$6.18
52-Week Range
$4.64
$24.50
Volume
3,344 shs
Average Volume
9,538 shs
Market Capitalization
$11.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Diffusion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.4% Upside
$9.50 Price Target
Short Interest
Healthy
1.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Diffusion Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.43) to ($7.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

478th out of 1,038 stocks

Pharmaceutical Preparations Industry

216th out of 510 stocks

DFFN stock logo

About Diffusion Pharmaceuticals (NASDAQ:DFFN) Stock

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Stock News Headlines

Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc. (DFFN)
DFFN: Phase 2 GBM Trial to Initiate 2H22…
Diffusion Pharmaceuticals GAAP EPS of -$2.22
5 Stocks Halted In Tuesday's Session
Why Diffusion Pharmaceuticals Shares Are Falling
See More Headlines
Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Company Calendar

Last Earnings
11/14/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/20/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DFFN
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$9.50
Low Stock Price Forecast
$9.50
Forecasted Upside/Downside
+64.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$17.13 per share

Miscellaneous

Free Float
1,998,000
Market Cap
$11.79 million
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Dr. Robert J. Cobuzzi Jr. (Age 57)
    Ph.D., Pres, CEO & Director
    Comp: $1.23M
  • Mr. William Karl Hornung (Age 53)
    Chief Financial Officer
    Comp: $450.68k
  • Mr. William Robert Elder J.D. (Age 39)
    Gen. Counsel & Corp. Sec.
    Comp: $338.36k
  • Dr. Christopher D. Galloway M.D. (Age 51)
    Chief Medical Officer
    Comp: $539.59k
  • Dr. David Randolph Jones M.D. (Age 59)
    Sr. Medical Advisor
  • Ms. Suzanne Cassidy
    Sr. Director & Head of Quality Assurance
  • Dr. Jennifer Llewelyn Ph.D.
    Sr. Director & Head of CMC
  • Ms. Raven Jaeger M.S. (Age 44)
    Chief Regulatory Officer
  • Ms. Kelly Hoy
    Director of Project Management
  • Mr. Harry Cook
    VP of Clinical Operations













DFFN Stock - Frequently Asked Questions

Should I buy or sell Diffusion Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DFFN shares.
View DFFN analyst ratings
or view top-rated stocks.

What is Diffusion Pharmaceuticals' stock price forecast for 2023?

1 brokers have issued 1 year price targets for Diffusion Pharmaceuticals' shares. Their DFFN share price forecasts range from $9.50 to $9.50. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.
View analysts price targets for DFFN
or view top-rated stocks among Wall Street analysts.

How have DFFN shares performed in 2022?

Diffusion Pharmaceuticals' stock was trading at $15.25 at the beginning of the year. Since then, DFFN stock has decreased by 62.1% and is now trading at $5.7777.
View the best growth stocks for 2022 here
.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 21,400 shares, an increase of 35.4% from the October 31st total of 15,800 shares. Based on an average daily trading volume, of 6,700 shares, the short-interest ratio is currently 3.2 days. Currently, 1.1% of the company's shares are short sold.
View Diffusion Pharmaceuticals' Short Interest
.

When is Diffusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our DFFN earnings forecast
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its quarterly earnings data on Monday, November, 14th. The company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.69.

When did Diffusion Pharmaceuticals' stock split?

Diffusion Pharmaceuticals's stock reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Who are Diffusion Pharmaceuticals' major shareholders?

Diffusion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.57%) and Renaissance Technologies LLC (2.16%). Insiders that own company stock include Jane H Hollingsworth, Robert Joseph Jr Cobuzzi and William Robert Elder.
View institutional ownership trends
.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $5.78.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $11.79 million. The company earns $-24,100,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for the company is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.

This page (NASDAQ:DFFN) was last updated on 11/29/2022 by MarketBeat.com Staff